Inborn errors of metabolism (IEM) are genetic disorders in which specific enzyme defects interfere with the normal metabolism of exogenous (dietary) or endogenous protein, carbohydrate, or fat. In the U.S., many IEM are detected through state newborn screening (NBS) programs. To inform research on IEM and provide necessary resources for researchers, we are providing: tabulation of ten-year state NBS data for selected IEM detected through NBS; costs of medical foods used in the management of IEM; and an assessment of corporate policies regarding provision of nutritional interventions at no or reduced cost to individuals with IEM. The calculated IEM incidences are based on analyses of ten-year data (2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011) from the National Newborn Screening Information System (NNSIS). Costs to feed an average person with an IEM were approximated by determining costs to feed an individual with an IEM, minus the annual expenditure for food for an individual without an IEM. Both the incidence and costs of nutritional intervention data will be useful in future research concerning the impact of IEM disorders on families, individuals and society.
Introduction
Inborn errors of metabolism (IEM) are genetic disorders in which specific enzyme defects interfere with the normal metabolism of exogenous (dietary) or endogenous protein, carbohydrate, or fat [1] . As a result of reduced or absent enzyme activity, toxic compounds may build up in the blood and brain, and other compounds may become deficient leading to adverse health outcomes. This definition is the theoretical basis for the use of nutritional interventions, which can bypass or overcome the metabolic consequences for some IEM. Early diagnosis and treatment at or near birth can often counter the adverse effects of some IEM, resulting in normal or near normal health outcomes. In many cases, nutritional interventions are the primary therapies used to manage these disorders and are required lifelong [1] .
A National Institutes of Health (NIH) initiative, Nutrition and Dietary Supplement Interventions for Inborn Errors of Metabolism (NDSI-IEM), was launched in 2010 to identify gaps in knowledge concerning the safety, efficacy, and effectiveness of nutritional treatments, including dietary supplements, for IEM that would benefit from evidence-based research [1] . To inform research on IEM and provide necessary resources for researchers, we are providing previously unpublished tabulations of ten-year state incidence data for selected IEM detected through newborn screening (NBS). Additionally, we are providing approximated costs of medical foods used in the management of IEM and an assessment of corporate policies regarding provision of nutritional interventions to individuals with IEM at no or reduced cost. As the landscape of our health care system changes over the next few years, these data will be needed for assessing adequacy of states' reimbursement and coverage policies and practices for nutritional interventions for individuals with IEM.
Background

National newborn screening data collection
From 1989 to 2011, all U.S. NBS programs voluntarily contributed case finding and other performance evaluation information to the Council of Regional Networks for Genetic Services (CORN) and to the National Newborn Screening and Genetics Resource Center (now the National Newborn Screening and Global Resource Center-NNSGRC) through the National Newborn Screening Information System (NNSIS). These data were intended for both self-and inter-program evaluation. This dataset currently represents the only comprehensive national NBS data available.
Originally, the U.S. national NBS data were collected annually from each screening program using a multi-page questionnaire. The indicators for which data were collected addressed system quality assurance. They were developed through a consensus process that included a broad cross-section of laboratory and non-laboratory personnel working with (and in) public health NBS programs. The NBS program descriptors and indicators for which data were submitted by each program included:
• Conditions screened for which data were collected and available;
• Laboratories providing screening services in/for the NBS program;
• NBS program fees, collection mechanisms, and program elements covered by fees (including medical foods); • Age of newborns at time of screening (i.e. number screened at 0-12 h, 13-24 h, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, over 7 days); • Screening laboratory methodology for each screened condition;
• NBS programs' case definitions for:
o Out-of-range reporting (by condition) o Level of follow-up action required (telephone or letter and serum or repeat filter card) o Diagnosed clinical cases;
• Specimens received per year:
o Total of initial specimens and repeat specimens o Percentage of specimens unacceptable for analysis o Specimens reported with out-of-range results on initial and on repeat screening; • Number of diagnosed individuals for each condition including race/ ethnicity, sex, and time from birth until treatment was initiated; and, • Number of individuals requiring follow-up who could not be located (i.e., "lost to follow-up").
The data elements collected and used for monitoring program quality assurance were reviewed and their validity reconfirmed on multiple occasions over the time period of their collection. Initially (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) this data repository was a function of CORN and later (1999-2011) it became a responsibility of the NNSGRC, both Health Resources and Services Administration (HRSA) funded initiatives. Beginning in 2000, these data were reported via the Internet (the NNSIS) and were available to the general public. The data tabulated and reported here were collected, summarized and revalidated by each NBS program prior to discontinuation of NNSGRC data collection activities in 2011. A more comprehensive review of the history and functioning of the national NBS data repository has been published previously [2] .
Nutritional interventions for IEM
Nutritional interventions for IEM include medical foods and dietary supplements along with dietary modifications to exclude nutrients that cannot be metabolized due to the specific IEM. At least twenty-two IEM on the U.S. Secretary of Health and Human Services' Recommended Uniform Screening Panel (RUSP), which currently is composed of 31 conditions, require medical foods and/or dietary supplements to prevent death, intellectual disability or other adverse health outcomes [3] .
A "medical food," is defined in the Orphan Drug Act (Act) (21 U.S.C. 360ee (b) (3)) [4] . In section 5(b) of the Act, [4] a medical food is "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation." Additionally, under the Act, the use of medical foods is tied to the term rare disease or condition 2 : a medical food is for "… managing any disease or condition that occurs so infrequently in the United States that there is no reasonable expectation that a medical food for such disease or condition will be developed without assistance under subsection (a) 3 of this section."
Medical foods for IEM encompass two distinct product types. One type contains sufficient nutrients to meet the majority of nutritional 2 Under the Orphan Disease Act, a rare disease or condition means in the case of a drug, "any disease or condition which (a) affects less than 200,000 persons in the United States, or (b) affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug…".
3 Subsection (a) defines the authority of the Secretary to defray costs of developing medical foods for rare diseases: The Secretary may make grants to and enter into contracts with public and private entities and individuals to assist in (1) defraying the costs of qualified testing expenses incurred in connection with the development of drugs for rare diseases and conditions, (2) defraying the costs of developing medical devices for rare diseases or conditions, and (3) defraying the costs of developing medical foods for rare diseases or conditions. requirements, is disorder specific, and excludes the nutrient(s) that cannot be metabolized. For example, for phenylketonuria (PKU; now more accurately referred to as phenylalanine hydroxylase deficiency [5] ), phenylalanine is excluded; whereas, for fatty acid oxidation disorders, certain fatty acids are limited. Depending on the disorder, this product type includes drinks made by reconstituting powders, ready to drink products, customized modular products, and bars. The other type of medical food includes products that are modified to be low in protein. These are designed for use in natural protein-restricted diets and provide required energy, satiety, and variety in the diet (e.g. specially modified flour, cereals, and baked goods, meat and cheese substitutes, pasta, and rice). Dietary supplements provide for other unmet nutritional needs due to dietary restriction (e.g. essential amino acids, vitamins, or minerals) or are used in large doses to enhance enzyme activity (e.g. vitamins) or assist in the removal of toxic metabolites (e.g. carnitine). The U.S. Congress defined the term "dietary supplement" in the Dietary Supplement Health and Education Act (DSHEA) of 1994 [6] as a product taken by mouth that contains a "dietary ingredient" intended to supplement the diet. The "dietary ingredients" in these products may include such items as vitamins, minerals, herbs or other botanicals, or amino acids. Dietary supplements can also be extracts or concentrates, and may be found as tablets, capsules, softgels, gelcaps, liquids, and powders, or in other forms, such as bars. Information on the product label must not represent the product as a conventional food or a sole item of a meal or diet. DSHEA places dietary supplements in a special category under the general umbrella of "foods," not drugs, and requires that every supplement be labeled as a dietary supplement. For some IEM, dietary supplements are used as treatment modalities, often in large doses, and thus do not conform strictly to the definition of a dietary supplement. Additionally, they only rarely undergo the Food and Drug Administration approval process required for drugs.
Financing nutritional interventions for IEM
Since its inclusion in NBS, tandem mass spectrometry (MS/MS) screening has been shown to be a cost effective method for IEM detection. Many reports exist assessing the economics of screening for multiple conditions simultaneously [7] [8] [9] [10] or for individual conditions as part of a multi-analyte panel [11] [12] [13] [14] . Cost effectiveness modeling is complex and beyond the scope of our discussion here. It suffices to say that societal cost savings are positive, but the amount saved varies by condition, complexities of the screening infrastructure, and modeling assumptions.
Access to nutritional interventions for screened disorders throughout the life span of individuals with IEM is essential for optimal outcomes. The amounts and costs of medical foods and/or dietary supplements needed to prevent adverse health outcomes are variable and depend on the IEM, the nutritional products required, and the treated individual's age. Payment for medical foods for children identified with IEM is achieved through: (1) partial use of NBS fees by the state program and/ or funds from other state or federal programs; (2) third-party health care payers; or (3) families' or individuals' "out-of-pocket" purchases. At least 46 NBS programs charge a fee (usually to the birthing center) to pay for the cost of supporting their newborn screening system [15, 16] . In the review by Therrell et al. [16] , 37% of these programs reported that fee monies supported various non-laboratory program activities, including the provision of medical foods. In both public and private insurance programs, coverage may vary depending on factors that include the diagnosis, nutritional content of the medical food, age of the individual, and the method of administration (orally or by a feeding tube into the gastrointestinal tract). A 2010 analysis by the Secretary's Advisory Committee on Heritable Disorders in Newborns and Children [17] and others in 2010 and 2013 [18, 19] , showed that insurance coverage of medical foods and foods modified to be low in protein vary depending on the state of residence for the individual/ family or type of their insurance plan. Thirty-two states were found to mandate some form of private insurance coverage if certain disorders were identified through NBS.
A recent survey among families of children less than 18 years of age with IEM evaluated usage of nutritional interventions among, and the associated cost burden to, their families. The study revealed that 80% of children utilized at least two different types of nutritional products and almost half used three or more (e.g., a protein-containing medical food, plus foods modified to be low in protein, plus a dietary supplement) [19] . At the time of the survey, the costs of protein-containing medical foods were covered for most children through payment sources such as Medicaid, private insurance, and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), while payment for foods modified to be low in protein were covered for only 40% of children.
These studies documented that the full costs of medical foods and dietary supplements used to treat IEM are not covered completely by health care payers. As a result, families and individuals must bear a significant financial burden in order to provide recommended medical interventions across the lifespan for both children and adults [19] .
None of the previous studies examined coverage of NBS treatments under newer state health care payer systems. Furthermore, Federal Medicaid regulations are silent on coverage of nutritional interventions for IEM, although currently nutritional interventions are covered for children who qualify for Medicaid. Many state policies will undoubtedly change over time as individual states define their essential health benefits package. Analysis of the state policies addressing nutritional interventions for IEM that have emerged since enactment of new Federal laws and regulations is beyond the scope of this paper. Nonetheless, the way in which these policy changes affect access to essential medical therapies for treating IEM is one of the more critical research issues now and for the future.
Methods
IEM incidence data
To estimate the number of newborns with a screened IEM who are detected and diagnosed annually in the U.S., NBS data were obtained from the NNSIS for the period of 2001-2010. In order to confirm the accuracy of the recorded data, programs were provided with tables of cases reported for each disorder annually for the ten years for revalidation and correction (if necessary). Because many U.S. NBS programs expanded their screening panels for IEM during this time period, we also confirmed the screening start dates for disorders begun during the 10-year study period. Data from a limited number of U.S. NBS programs (four programs) could not be revalidated either because the data were no longer available to the state program or because of other program constraints (primarily personnel time and effort). In order to provide as complete a dataset as possible, and because the likelihood was high that the data initially input into the NNSIS were correctly entered, these data elements were included in our tables and tabulations (identified as such through footnotes).
Since IEM disease case-definitions are not standardized nationally, the definitions of confirmed cases were left to the discretion of NBS programs and their medical advisors throughout the period of data collection. Listings of the case definitions used were available as part of the online data system for comparison between programs. Where variations in case definitions existed, the specific differences often appeared to be subtle and rarely appeared to affect the nutritional treatment. For purposes of this report, we have assumed that physician subspecialists confirmed all IEM cases reported by NBS programs using generally agreed upon case-definitions.
The majority of U.S. NBS programs do not link birth records with NBS data [20] and therefore, most programs are not able to provide a valid non-duplicated tally of babies screened. For consistency, we obtained data on numbers of births by place of occurrence from the NNSIS, which had been obtained by request from the Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS), and we assumed complete birth coverage by the screening programs. In cases where data recording for a specific disorder began within the 10-year study period, we approximated the number of babies screened by assuming an even distribution of births monthly over the year. We then calculated the number of babies screened by multiplying the monthly average by the number of months for which data existed. In most instances data reporting began on the first day of the month, but when data reporting began on a date other than the first of the month, calculations were made to the nearest 1/2-month.
Estimate of average costs per year for medical foods for IEM
To estimate the costs associated with the use of nutritional intervention products, the appropriate literature and publically available national data were reviewed and relevant cost data were extracted to the extent possible. The costs of medical foods depend on the disorder, the individual's age, and the mechanisms through which individuals obtain these products. Thus, it is difficult to ascertain total societal costs for providing these products for all individuals at any one time. We created a table of conditions and their nutritional interventions and combined this with the 2001-2010 national incidence data as a way of summarizing the information to be considered. We then estimated the costs of medical foods containing protein plus the costs of foods modified to be low in protein for selected age groups. In order to determine the costs of medical foods in excess of what it costs to feed the average person within the selected life stage, we subtracted the estimated annual expenditure for food for an individual without an IEM. These costs were summarized in tabular form for inclusion in our report. Note that we have not attempted to estimate the costs of dietary supplements, whether used in addition to a medical food (e.g., homocystinuria) or used as a sole treatment modality (e.g., biotinidase deficiency) because costs vary too widely depending on where and from which company the product is obtained.
Corporate policies
To better understand the overall impact of commercial practices associated with providing IEM nutritional products to individuals with IEM and families at no or reduced cost, we identified 11 U.S. companies that manufacture and/or distribute medical food products specifically for the nutritional management of IEM. Of these, three (27%) make exempt infant formulas. 4 These three companies and five others also make medical foods with protein for children over age 1 (73% of total companies). Eight of the 11 companies make or distribute foods modified to be low in protein (73%), and three (27%) exclusively make products modified to be low in protein.
To understand the overall contribution of these industry practices to product availability for individuals, in the fall of 2012, one of us (KC) sent a short questionnaire to the eight companies in the United States that manufacture and/or distribute medical foods with protein for infants and individuals over 1 year of age. Replies were received from six of the eight companies (75%).
Results
National NBS data
Tabulations of the national NBS data on births by place of occurrence and confirmed cases are given in Tables 1-7 organized by the regional NBS and genetics collaboratives defined by the Maternal and Child Health Bureau, HRSA [21] [Note: Nevada was originally in Region 7 and was transferred to Region 6 in 2006 where it now resides.]. National summary incidence data and their treatment modalities are included in Table 8 . Summary data similarly collected and tabulated have been published for the previous 10-year period allowing comparisons for those IEM that were included on state NBS panels during that time period (available at: http://genes-r-us.uthscsa.edu/sites/genes-r-us/ files/resources/genetics/10yeardatareport.pdf; accessed March 19, 2014) . A published summary of the 1991-2000 data also exists [2] . It is important to note that birth data used in NBS studies must be based on place of birth occurrence rather than residence. While current birth data by place of occurrence are available from the NCHS on request, 4 Exempt infant formulas do not include the offending nutrient(s); e.g. infant formulas for PKU do not contain phenylalanine. They must, however, meet the regulatory requirements of standard infant formulas, with the exception that they are exempt from applicable good manufacturing processes, nutrient content, and labeling requirements. 
Costs of nutritional interventions
Along with the national summary incidence data in Table 8 , summary information on the nutritional interventions employed with the IEM studied are included. These summary data provide a basis for estimating costs relative to treatment expenses for the IEM listed. Based on these data, nutritional costs for managing a typical IEM over and above costs for persons without an IEM are estimated for four age groups (see Table 9 ). Annual costs range from $2254 for an infant to almost $25,000 for an adult male or pregnant woman.
Corporate policies regarding nutritional products for IEM
A limited number of manufacturers and distributors of medical foods for IEM currently serve the U.S. Of the six companies who responded to the request for information about policies regarding the provision of medical foods to individuals, all stated that they provide products to individuals at no or reduced cost in specific or limited situations. Most often, the amount and types of products provided and length of provision depended on individual circumstances. At least two companies provide products throughout a pregnancy, and one has no limit on the length of time that they will provide a product for a specific individual. Most of the companies also noted a willingness to help individuals and families obtain coverage from health care payers or other sources. Based on the responses, the overall contribution of nutritional products at no or reduced cost to individuals must be viewed only as a bridging mechanism until coverage from other sources can be obtained.
Discussion
In order to accurately address issues related to cost and treatment for IEM detected through NBS, it is essential to know the number of confirmed cases detected nationally. We obtained the most comprehensive case data available and have tabulated it here as an aid in future research. The NBS incidence data are presented in regional format in order to provide for comparisons with previous data similarly tabulated (available at: http://genes-r-us.uthscsa.edu/sites/ genes-r-us/files/resources/genetics/10yeardatareport.pdf; accessed March 19, 2014 ). This regional format should facilitate future discussions concerned with coordinating regional activities focused on access to care.
Screening for the majority of IEM currently on the RUSP was initiated during the decade from 2001 to 2010; summary incidence data for the ten-year period of 1991-2000 are limited to only a few IEM. We elected to revalidate and use the 2001-2010 data since these data covered a time period in which a more sensitive screening technique, tandem mass spectrometry (MS/MS), was used in the NBS laboratories and when screening results for IEM on the RUSP were more widely available. We used the combined reported incidences for PKU and clinically significant hyperphenylalaninemia in our calculations for these reasons: programs reported both conditions; the case definitions appeared to vary and overlap; and both conditions require nutritional interventions. The only previously published comprehensive national incidence data for the U.S. addressed the 10-year period immediately preceding our study period, and these data were collected and validated in the same way as the data in our study [2] . Only a few IEM were included in the earlier study since most Difficulties with analyzing national incidence data are encountered because of the lack of national standards governing NBS data, such as uniform case definitions. Early attempts by CORN to apply case definitions to data submitted by NBS programs resulted in a poor response rate, since consensus case-definitions did not exist. Therefore, beginning in 1991, NBS programs were asked to submit data to the national NBS data repository using their own case definitions. The definitions used by each program were then tabulated and reported separately with the hope that by sharing case definitions, consensus would be generated thus improving the national data [2] . Between 1991 and 2011, all U.S. NBS programs except New York contributed data to the national database. New York data were maintained on a state-supported website and were periodically copied into the NNSIS to form a comprehensive national dataset.
Conclusion
Despite challenges and their need for future resolution, we still were able to tabulate credible national incidence data in order to inform our discussion. Nevertheless, future research depends on access to a robust data system. As illustrated by our efforts to obtain national incidence data for the various conditions detected through NBS, the lack of national consensus on case definitions restricts the degree of accuracy of national incidence numbers essential to any research and evaluation. Similarly, a voluntary national data system that depends on unfunded cooperation and collaboration among the 51 national partnering programs (50 states and the District of Columbia) results in tenuous data collection that is often reported slowly and may be prone to inaccuracies. The inability of most U.S. NBS programs to compare births to screens in real time, so that screening all babies can be assured and reliable screening data can be obtained for calculating accurate disease incidences, remains a challenge. While we assumed 100% screening coverage and used births reported by vital records managers and not the NBS program, more precise coverage data are needed for more accurate incidence calculations. Linking birth records to NBS results is one way of overcoming this data collection challenge. Such linkages would provide the accurate newborn screening coverage data needed to provide accurate incidence calculations. Left untreated, infants and children with IEM experience serious adverse health outcomes including intellectual disability, behavioral dysfunction, inadequate growth, abnormal development, nutrient deficiencies, and sequelae that require complex hospital care. Furthermore, with the success of NBS and appropriate nutritional interventions, there are adults living with IEM. The nutritional cost data presented serve to highlight the challenges facing individuals and families seeking access to affordable medical foods as part of their continuing lifelong treatment.
Part of future translational research must include ways to assess affordable access to medical foods. As one example, investigation and development of a thorough understanding of impediments and challenges to making nutritional interventions available to individuals with IEM and their families might be initiated. Research would include partnering with public health and health care professionals and payers and families and individuals through disease advocacy organizations to identify and provide the information needed by policymakers to take actions to eliminate identified barriers. Areas to be investigated could include private health insurance plans/ mandates, state and federal supplemental programs, and the impact of federal laws and regulations on state policies concerning provision of medical foods and dietary supplements. Not only would such research help provide the foundation needed to remove barriers to treatments developed through medical research, but removing these barriers to treatments would facilitate research on the clinical spectrum of the disease as well as a better understanding of the effect of nutritional interventions on the long-term health outcomes of individuals with IEM.
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